Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13-hydroxyibogamine
- Development stage
- Preclinical
- Lead developer
- Nirvana Life Sciences
- Modality
- Small Molecules
01
Overview
13-Hydroxyibogamine is a small molecule, hydroxylated ibogaine-related metabolite analog under preclinical development by Nirvana Life Sciences. It is the 13-hydroxy variant of noribogaine (12-hydroxyibogamine), which is the primary active metabolite of ibogaine. Nirvana Life Sciences is developing a batch-scale synthesis of noribogaine and its 13-hydroxy variant as part of their ibogaine alkaloid program. The intended therapeutic application of 13-hydroxyibogamine is the treatment of substance addiction, including drug and alcohol addiction. The specific molecular targets and mechanism of action of 13-hydroxyibogamine have not been formally characterized or publicly disclosed.
- Other names
- 13-hydroxy variant of ibogaine metabolite13-hydroxy variant of noribogaine
Beyond the preview
Go deeper on 13-hydroxyibogamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 13-hydroxyibogamine.